Johnson & Johnson (JNJ) analysis
Johnson & Johnson
Sector:Health Care · Pharmaceuticals and Medical Devices
Country:United States
Profile and moat
Johnson & Johnson after the consumer spin is a pharmaceuticals and med-tech company, still diversified by therapy and device but no longer a baby-powder-and-Band-Aid conglomerate in the listed perimeter. Cash flows are long-duration, regulated, and exposed to patent cliffs, trial failures and litigation — the last of which has defined the public narrative for years.
The equity is often owned as a defensive health-care compounder and dividend aristocrat with an AAA-era credit culture. Innovation (oncology, immunology, surgery robotics and devices) is the growth engine; loss of exclusivity is the decay engine. You cannot read JNJ as a 'wide moat forever' without the patent calendar.
Capital allocation is dividends, bolt-on deals, and R&D. Leverage is typically conservative. The radar will look calmer than a biotech and less exciting than an AI chip name; that is the business.